Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun;44(6):2408-24.
doi: 10.1016/j.ejmech.2008.09.031. Epub 2008 Oct 2.

Acyclic nucleoside bisphosphonates: synthesis and properties of chiral 2-amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines

Affiliations

Acyclic nucleoside bisphosphonates: synthesis and properties of chiral 2-amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines

Petra Doláková et al. Eur J Med Chem. 2009 Jun.

Abstract

2-Amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines bearing two equal or different achiral or chiral phosphonoalkoxy chains have been prepared either by aromatic nucleophilic substitution of 2-amino-4,6-dichloropyrimidine or by alkylation of 4,6-dihydroxy-2-(methylsulfanyl)pyrimidine with appropriate phosphonate-bearing building block. Alkylation of 4,6-dihydroxy-2-(methylsulfanyl)pyrimidine proved to be the method of choice for efficient preparation of variety of bisphosphonates. The enantiomeric purity of selected compounds was determined by capillary electrophoresis. Antiviral activity of bisphosphonates is discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acyclic nucleoside phosphonates.
Figure 2
Figure 2
Acyclic nucleoside bisphosphonates.
Figure 3
Figure 3
A: CE separation of enantiomers 27a (S), 0.1mM and 27b (R), 0.2 mM in chiral BGE (background electrolyte) composed of 50 mM borax, adjusted by NaOH to pH 10.0, with chiral selector β-cyclodextrin (20 mg/ml). B: CE analysis of enantiomer 27a in the above chiral BGE. C: CE analysis of enantiomer 27b in the above chiral BGE. eof = electroosmotic flow marker.
Scheme 1
Scheme 1
Synthesis of bis-HPMPO derivatives.
Scheme 2
Scheme 2
Alkylation of 4,6-(dihydroxy)pyrimidines.
Scheme 3
Scheme 3
Synthesis of bisphosphonates by alkylation of 4,6-(dihydroxy)-2-(methylsulfanyl)pyrimidine.
Scheme 4
Scheme 4
Alkylation of 2-amino-4,6-(disulfanyl)pyrimidine.
Scheme 5
Scheme 5
Synthesis of alkoxyalkyl esters of bisphosphonates.

Similar articles

Cited by

References

    1. De Clercq E, Holý A. Nature Rev Drug Discov. 2005;4:928–940. - PubMed
    2. Holý A. Curr Pharm Des. 2003;9:2567–2592. - PubMed
    3. Khandazhinskaya A, Yasko M, Shirokova E. Curr Med Chem. 2006;13:2953–2980. - PubMed
    4. De Clerq E. Biochem Pharmacol. 2007;73:911–922. - PubMed
    1. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. Antivir Chem Chemother. 1997;8:1–23.
    2. Ying C, De Clercq E, Neyts J. J Viral Hepat. 2000;7:79–83. - PubMed
    1. Starrett JE, Jr, Tortolani DR, Hitchcock MJ, Martin JC, Mansuri MM. Antiviral Res. 1992;19:267–273. - PubMed
    1. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A. Hepatology. 2000;32:129–134. - PubMed
    2. Dando TM, Plosker GL. Drugs. 2003;63:2215–2234. - PubMed
    1. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ. AIDS Res Hum Retroviruses. 1997;13:707–712. - PubMed
    2. Srinivas RV, Fridland A. Antimicrob Agents Chemother. 1998;42:1484–1487. - PMC - PubMed
    3. Suruga Y, Makino M, Okada Y, Tanaka H, De Clercq E, Baba M. J Acquired Immune Defic Syndr Hum Retrovirol. 1998;18:316–322. - PubMed
    4. Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, Tarara PR, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC. J Virol. 2000;74:1767–1774. - PMC - PubMed
    5. Grim SA, Romanelli F. Annals of Pharmacother. 2003;37:849–859. - PubMed

Publication types

MeSH terms

LinkOut - more resources